McKesson Corporation
J.P. Morgan Healthcare Conference
Brian Tyler
Chief Executive Officer
January 12, 2021
Cautionary Statements
Except for historical information contained in this presentation, matters discussed may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. Forward-looking statements may be identified by their use of terminology such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "intends", "plans", "estimates" or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans, assumptions or intentions may also include forward-looking statements. We encourage investors to read the important risk factors described in the company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission.
These risk factors include, but are not limited to: we experience costly and disruptive legal disputes, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we experience cybersecurity incidents and might experience significant computer system compromises or data breaches; we might experience significant problems with information systems or networks; we may be unsuccessful in retail pharmacy profitability; we might be harmed by large customer purchase reductions, payment defaults or contract non-renewal; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by changes or disruptions in product supply and we have experienced and may experience difficulties in sourcing products due to the effects of the COVID-19 pandemic on supply chains; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by an economic slowdown (including the effects we have experienced from the COVID-19 pandemic) or recession and by disruption in capital and credit markets that might impede our access credit, increase our borrowing costs and impair the financial soundness of our customers and suppliers; we might be adversely impacted by fluctuations in foreign currency exchange rates; we might be adversely impacted by events outside of our control, such as widespread public health issues (including the effects we have experienced from the COVID-19 pandemic), natural disasters, political events and other catastrophic events; and we face uncertainties and risks related to vaccination distribution programs.
GAAP / Non-GAAP Reconciliation
In an effort to provide additional and useful information regarding the Company's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials in this presentation include non-GAAP information. The Company believes the presentation of non- GAAP measures provides useful supplemental information to investors with regard to its operating performance as well as comparability of financial results period-over-period. A reconciliation of the non-GAAP information to GAAP, and other related information is available in the tables accompanying each period's earnings press release, materials furnished to the SEC, and posted to www.mckesson.com under the "Investors" tab.
Our Vision:
To improve care in every setting - one product, one partner,
one patient at a time
Favorable trends lead to continued growth in the U.S. healthcare market
U.S. Market Dynamics
4.2% Total Pharmaceutical Market Growth (5-year CAGR)1
12.5% Oncology Market Growth (5-year CAGR)1
6 Biosimilar launches
(2020)
12.0% Access, Affordability & Adherence Market Growth2
Favorable Trends
Innovative therapies
Shifting sites of care
Aging population
Value-based care
Digitization of healthcare
See appendix for footnotes
4
Leading positions with differentiated assets and capabilities
Delivering | Facilitating 19B+ healthcare transactions, | |
1/3 of all | ||
enabling >$5B in annual prescription savings | ||
prescription | ||
medicine | ||
in North America | Delivering medical-surgical | #1 distributor in |
supplies and services to | community oncology | |
250,000+ customers | and key specialties |
500+
biopharma brands
served across
>94% of
therapeutic areas
More than 12,000 owned and banner
Partnering with the
U.S. Government to support
Operation Warp Speed
Serving over 10,000 physicians each day through Specialty Provider distribution and GPO services
pharmacies in Europe
and Canada
Statistics as of March 31, 2020
5
Delivering on key priorities to maximize growth
Strengthen the Core &
Streamline the Business
- Completed Change Healthcare exit and created German wholesale JV with Walgreens Boots Alliance
- Grew FY20 Adjusted Operating Profit3 across every segment
- Guiding to $2.3B to $2.7B of Free Cash Flow3,4 in FY21, underpinned by focus on working capital efficiencies
- Realigned organizational structure to better serve customers and patients
- Operating as the centralized distributor of refrigerated and frozen COVID-19 vaccines and ancillary supply kits in the U.S.
Invest in Growth &
New Opportunities
- Invested over $100M5 internally into Oncology and Biopharma Services assets to support future growth
- Launched OntadaTM, an oncology technology and real-world insights business
- Expanded Access for More Patients (AMP) to transform patient access to specialty therapies
- Grew sourcing partnerships and laboratory distribution capabilities to meet demand resulting from COVID-19
- Advanced enterprise-wide data and analytics initiatives and technology modernization
See appendix for footnotes
6
Executing a clear growth strategy to drive long-term value
Oncology | Biopharma Services | |
Providers |
Pharmacies | Biopharma |
Patients |
Payers
Strengthening the core & streamlining the business
enables further investment and innovation
7
Targeted investments over time have enhanced our portfolio of leading and differentiated oncology assets
2007 | 2008 | 2010 | 2016 | 2020 |
Onmark GPO
Distributor of | Community oncology | The largest community | Oncology-focused | Internally developed |
Specialty | Group Purchasing | oncology network | specialty pharmacy | oncology technology |
Pharmaceuticals | Organization | and insights business |
Clinical trials | Radiation and |
medical oncology | |
These investments added:
Distribution | Scale to | Deep oncology | Oncology capability | Enhanced data and |
capabilities | provider base | expertise | and scale | research capabilities |
8
Ontada: Delivering real-world insights for real-world impact
Biopharma
9
Ontada is a technology and insights business dedicated to transforming the fight against cancer
Launched in December 2020 | |
Value Proposition | 2,000+ |
oncology providers use the | |
iKnowMedSM EHR |
Leveraging data and | Delivering evidence- | ||||
insights to accelerate | |||||
driven care and | |||||
innovation and better | |||||
improved outcomes | |||||
support the patient | |||||
for patients | |||||
journey | Providers | ||||
1.2M+ | 2M+ | ||||
patients treated | patient records | ||||
annually within | available for | ||||
The US Oncology | research | ||||
Network | |||||
Leading Biopharma Services assets create a powerful Prescription Technology Solutions business
2006 | 2017 | 2018 | 2020 | |
Prescription Technology | ||||
Solutions (RxTS) | ||||
• Pharmacy claims switch & | • Automated insurer approval | • Hub services and patient | • | Automated hub services and |
automated copay programs | for drug coverage | assistance programs | aligned assets | |
• Processing >19B | • Network of ~750K providers | • Specialty disease state | • | 500+ brands served across |
transactions annually | expertise | >94% of therapeutic areas | ||
• Network of ~50K pharmacies | • Integrated with 75% of EHRs | • | Automated communication to | |
get patients on innovative | ||||
therapies faster |
Increasing value to biopharma and enabling >$5B in prescription savings
10
How McKesson has responded to the COVID-19 pandemic
Our Team
-
Extended medical benefits
and expanded telehealth options for employees - Invested approximately $45M to support frontline employees and communities
- Mandatory telecommuting for office-based employees without sacrificing productivity
- Enhanced safety measures in our distribution centers and offices
Supply Chain
- Expanded partnerships to secure additional product and meet incremental customer demand
- Brought critical supplies to the U.S. in two to three days versus 30 to 40 days
- Distributed critical product inventory to areas and sites of care with greatest need
- Zero production time lost across our distribution centers
Vaccine Support
- Operating as the centralized distributor of refrigerated and frozen COVID-19 vaccines
- Managing the assembly of supply kits needed to administer COVID-19 vaccines
- Stood up nine distribution centers to support kitting and distribution operations
- On-targetwith U.S. Government's plans to assemble ancillary kits and distribute allocated vaccines
11
We are amplifying our Sustainability & ESG strategy and action
Recent Highlights
- Recognized for diversity & inclusion efforts in 2020:
- Forbes: one of best employers for diversity
- Disability Equality Index®
- Human Rights Campaign
- Military Friendly® Employer
- Appointed Chief Impact Officer
- Women and people of color comprise over 50% of our Board of Directors and 50% of our executive officers
- Joined the UN Global Compact, demonstrating commitment to making progress against the UN Sustainable Development Goals
- Entered into contract to purchase local, physical renewable energy for most of our locations in Texas
- On track to realize a 40% reduction
in lighting electricity usage through expanded LED lighting
Advancing Sustainability & ESG across the enterprise to deliver greater value for both business and society
12
Disciplined and balanced capital allocation approach
Operating Cash Flow
FY18 - FY20: $12.8B
Disciplined Capital Allocation
Strategic Growth | Return Capital | |||||||
to Shareholders | ||||||||
M&A | $3.9B | Dividends | $0.9B | |||||
Internal Investments | $1.6B | Share Repurchases | $5.3B | |||||
Underpinned by Maintenance of Investment-Grade Credit Rating
$1.1B of Net Long-Term Debt Reduction
13
McKesson delivers shareholder value
Investing in | Driving | Focused Capital | Serving |
Growth Areas | Innovation | Deployment | Communities |
Transforming the culture for long-term success
14
Appendix
- Source: IQVIA, National Sales Perspectives, December 2020. Five- year CAGR beginning 2015 and ending November 2020. IQVIA expressly reserves all rights, including rights of further copying, distribution and republication. McKesson does not warrant or represent the accuracy of IQVIA data or McKesson's interpretations of IQVIA data. Any subsequent use or interpretation of this data will be the liability of the receiving party and not of McKesson or IQVIA.
- Source: Bain Consulting analysis, market reports, internal market sizing. Three-yearforward-looking CAGR beginning 2020 and ending 2023.
- This financial measure is a non-GAAP financial measure. For an explanation of this financial measure and a reconciliation to the most directly comparable GAAP measure, refer to our Investor Relations website at https://www.investor.mckesson.com.
- Reflects information as of November 3, 2020, based on assumptions then described.
- Figure includes capital expenditures and operating expenses for the period Q1 FY19 through Q2 FY21.
16
Attachments
- Original document
- Permalink
Disclaimer
McKesson Corporation published this content on 12 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2021 14:09:03 UTC